Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	prostaglandin transmembrane transporter activity	SLCO1B1 SLCO1B3	1.15e-04	14	23	2	GO:0015132
GeneOntologyMolecularFunction	icosanoid transmembrane transporter activity	SLCO1B1 SLCO1B3	1.32e-04	15	23	2	GO:0071714
GeneOntologyMolecularFunction	oligopeptide transmembrane transporter activity	SLCO1B1 SLCO1B3	1.51e-04	16	23	2	GO:0035673
GeneOntologyMolecularFunction	sodium-independent organic anion transmembrane transporter activity	SLCO1B1 SLCO1B3	1.92e-04	18	23	2	GO:0015347
GeneOntologyMolecularFunction	bile acid transmembrane transporter activity	SLCO1B1 SLCO1B3	6.96e-04	34	23	2	GO:0015125
GeneOntologyMolecularFunction	amide transmembrane transporter activity	SLCO1B1 SLCO1B3	1.06e-03	42	23	2	GO:0042887
GeneOntologyMolecularFunction	organic hydroxy compound transmembrane transporter activity	SLCO1B1 SLCO1B3	2.92e-03	70	23	2	GO:1901618
GeneOntologyMolecularFunction	lipid transmembrane transporter activity	SLCO1B1 SLCO1B3	3.17e-03	73	23	2	GO:0170055
GeneOntologyMolecularFunction	monocarboxylic acid transmembrane transporter activity	SLCO1B1 SLCO1B3	4.78e-03	90	23	2	GO:0008028
GeneOntologyBiologicalProcess	pigment catabolic process	SLCO1B1 SLCO1B3	5.94e-05	11	22	2	GO:0046149
GeneOntologyBiologicalProcess	heme catabolic process	SLCO1B1 SLCO1B3	5.94e-05	11	22	2	GO:0042167
GeneOntologyBiologicalProcess	porphyrin-containing compound catabolic process	SLCO1B1 SLCO1B3	8.41e-05	13	22	2	GO:0006787
GeneOntologyBiologicalProcess	tetrapyrrole catabolic process	SLCO1B1 SLCO1B3	9.81e-05	14	22	2	GO:0033015
GeneOntologyBiologicalProcess	sodium-independent organic anion transport	SLCO1B1 SLCO1B3	1.13e-04	15	22	2	GO:0043252
GeneOntologyBiologicalProcess	oligopeptide transport	SLCO1B1 SLCO1B3	2.71e-04	23	22	2	GO:0006857
GeneOntologyBiologicalProcess	xenobiotic metabolic process	SLCO1B1 SLCO1B3 SULT1A2	4.38e-04	141	22	3	GO:0006805
HumanPheno	Conjunctival icterus	PKHD1 SLCO1B1 SLCO1B3	1.90e-07	7	10	3	HP:0032106
HumanPheno	Bilirubinuria	SLCO1B1 SLCO1B3	3.47e-06	2	10	2	HP:0031811
HumanPheno	Conjugated hyperbilirubinemia	PKHD1 SLCO1B1 SLCO1B3	4.43e-05	38	10	3	HP:0002908
HumanPheno	Porphyrinuria	SLCO1B1 SLCO1B3	9.65e-05	8	10	2	HP:0010473
HumanPheno	Intermittent jaundice	SLCO1B1 SLCO1B3	1.24e-04	9	10	2	HP:0001046
HumanPheno	Abnormal circulating porphyrin concentration	SLCO1B1 SLCO1B3	3.59e-04	15	10	2	HP:0010472
HumanPheno	Digenic inheritance	SLCO1B1 SLCO1B3	4.10e-04	16	10	2	HP:0010984
MousePheno	abnormal circulating cholesterol level	SLCO1B1 SLCO1B3 ZNF644 TXNDC11 PDZK1 FADS1 MALRD1	1.34e-04	823	21	7	MP:0000180
MousePheno	abnormal cholesterol level	SLCO1B1 SLCO1B3 ZNF644 TXNDC11 PDZK1 FADS1 MALRD1	1.86e-04	867	21	7	MP:0003947
MousePheno	abnormal sterol level	SLCO1B1 SLCO1B3 ZNF644 TXNDC11 PDZK1 FADS1 MALRD1	2.04e-04	880	21	7	MP:0012224
MousePheno	abnormal kidney weight	PKHD1 THOC2 FAM120C FADS1	2.34e-04	208	21	4	MP:0002707
MousePheno	abnormal cholesterol homeostasis	SLCO1B1 SLCO1B3 ZNF644 TXNDC11 PDZK1 FADS1 MALRD1	2.98e-04	936	21	7	MP:0005278
MousePheno	abnormal hepatobiliary system physiology	PKHD1 SLCO1B1 SLCO1B3 SULT1A2 MALRD1	3.76e-04	433	21	5	MP:0002139
MousePheno	increased circulating cholesterol level	SLCO1B1 SLCO1B3 ZNF644 TXNDC11 PDZK1	5.11e-04	463	21	5	MP:0005178
Domain	OA_transporter	SLCO1B1 SLCO1B3	9.50e-05	12	23	2	IPR004156
Domain	OATP	SLCO1B1 SLCO1B3	9.50e-05	12	23	2	PF03137
Domain	Kazal_2	SLCO1B1 SLCO1B3	8.91e-04	36	23	2	PF07648
Domain	KAZAL	SLCO1B1 SLCO1B3	1.45e-03	46	23	2	SM00280
Domain	KAZAL_2	SLCO1B1 SLCO1B3	1.71e-03	50	23	2	PS51465
Domain	Kazal_dom	SLCO1B1 SLCO1B3	1.78e-03	51	23	2	IPR002350
Domain	MFS	SLCO1B1 SLCO1B3	7.74e-03	108	23	2	PS50850
Domain	MFS_dom	SLCO1B1 SLCO1B3	1.17e-02	134	23	2	IPR020846
Pathway	REACTOME_ATORVASTATIN_ADME	SLCO1B1 SLCO1B3	6.16e-05	9	19	2	M45020
Pathway	REACTOME_TRANSPORT_OF_ORGANIC_ANIONS	SLCO1B1 SLCO1B3	9.40e-05	11	19	2	M930
Pathway	REACTOME_TRANSPORT_OF_ORGANIC_ANIONS	SLCO1B1 SLCO1B3	1.13e-04	12	19	2	MM15476
Pathway	WP_ENTEROHEPATIC_CIRCULATION_OF_BILE_ACIDS	SLCO1B1 SLCO1B3	1.13e-04	12	19	2	M48096
Pathway	WP_SULFATASE_AND_AROMATASE_PATHWAY	SLCO1B1 SLCO1B3	1.55e-04	14	19	2	M48085
Pathway	REACTOME_HEME_DEGRADATION	SLCO1B1 SLCO1B3	1.79e-04	15	19	2	M27060
Pathway	REACTOME_ATORVASTATIN_ADME	SLCO1B1 SLCO1B3	1.79e-04	15	19	2	MM15697
Pathway	REACTOME_RECYCLING_OF_BILE_ACIDS_AND_SALTS	SLCO1B1 SLCO1B3	2.60e-04	18	19	2	M4862
Pathway	REACTOME_RECYCLING_OF_BILE_ACIDS_AND_SALTS	SLCO1B1 SLCO1B3	2.90e-04	19	19	2	MM14612
Pathway	REACTOME_HEME_DEGRADATION	SLCO1B1 SLCO1B3	3.22e-04	20	19	2	MM14721
Pathway	REACTOME_DRUG_ADME	SLCO1B1 SLCO1B3 SULT1A2	5.15e-04	119	19	3	MM15692
Pathway	REACTOME_METABOLISM_OF_PORPHYRINS	SLCO1B1 SLCO1B3	5.92e-04	27	19	2	M1088
Pathway	WP_DISORDERS_OF_BILE_ACID_SYNTHESIS_AND_BILIARY_TRANSPORT	SLCO1B1 SLCO1B3	6.84e-04	29	19	2	M45551
Pathway	REACTOME_METABOLISM_OF_PORPHYRINS	SLCO1B1 SLCO1B3	8.33e-04	32	19	2	MM14719
Pathway	REACTOME_TRANSPORT_OF_VITAMINS_NUCLEOSIDES_AND_RELATED_MOLECULES	SLCO1B1 SLCO1B3	1.37e-03	41	19	2	MM15075
Pathway	REACTOME_TRANSPORT_OF_VITAMINS_NUCLEOSIDES_AND_RELATED_MOLECULES	SLCO1B1 SLCO1B3	1.50e-03	43	19	2	M881
Pathway	REACTOME_BILE_ACID_AND_BILE_SALT_METABOLISM	SLCO1B1 SLCO1B3	1.57e-03	44	19	2	M499
Pathway	REACTOME_BILE_ACID_AND_BILE_SALT_METABOLISM	SLCO1B1 SLCO1B3	1.65e-03	45	19	2	MM14751
Pubmed	The Diet1 locus confers protection against hypercholesterolemia through enhanced bile acid metabolism.	SLCO1B1 SLCO1B3 MALRD1	7.19e-08	13	23	3	11682476
Pubmed	Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	18314419
Pubmed	OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	21691816
Pubmed	Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	17412826
Pubmed	SLCO1B1 and SLCO1B3 genetic mutations in Taiwanese patients with Rotor syndrome.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	36964102
Pubmed	Expression Patterns of Organic Anion Transporting Polypeptides 1B1 and 1B3 Protein in Human Pediatric Liver.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	27098745
Pubmed	Introduction of aromatic ring-containing substituents in cyclic nucleotides is associated with inhibition of toxin uptake by the hepatocyte transporters OATP 1B1 and 1B3.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	24740327
Pubmed	Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	21719246
Pubmed	Structure of human drug transporters OATP1B1 and OATP1B3.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	37723174
Pubmed	Organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3: genetic variability and haplotype analysis in white Canadians.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	20877131
Pubmed	Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	24855184
Pubmed	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	23340295
Pubmed	Linking organic anion transporting polypeptide 1B1 and 1B3 (OATP1B1 and OATP1B3) interaction profiles to hepatotoxicity - The hyperbilirubinemia use case.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	28063966
Pubmed	Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	26474710
Pubmed	Interaction of Human OATP1B1 with PDZK1 Is Required for Its Trafficking to the Hepatocyte Plasma Membrane.	SLCO1B1 PDZK1	4.18e-07	2	23	2	37442606
Pubmed	Effects of anthocyans on the expression of organic anion transporting polypeptides (SLCOs/OATPs) in primary human hepatocytes.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	25578040
Pubmed	Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	16534140
Pubmed	UGT-dependent regioselective glucuronidation of ursodeoxycholic acid and obeticholic acid and selective transport of the consequent acyl glucuronides by OATP1B1 and 1B3.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	31299240
Pubmed	Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	29777022
Pubmed	Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	26191226
Pubmed	In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	23886114
Pubmed	Effects of Rifampin, a potent inducer of drug-metabolizing enzymes and an inhibitor of OATP1B1/3 transport, on the single dose pharmacokinetics of anacetrapib.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	23670789
Pubmed	OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	21787759
Pubmed	Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	22240838
Pubmed	Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	18321482
Pubmed	Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	24989890
Pubmed	Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	22771883
Pubmed	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	17496208
Pubmed	Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	24194513
Pubmed	Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	18180273
Pubmed	Rotor Syndrome	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	23236639
Pubmed	Modulation of transporter activity of OATP1B1 and OATP1B3 by the major active components of Radix Ophiopogonis.	SLCO1B1 SLCO1B3	4.18e-07	2	23	2	29944058
Pubmed	Interaction Between Sex and Organic Anion-Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in Mice.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	30955241
Pubmed	Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	20660695
Pubmed	Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	31047942
Pubmed	Influence of drug formulation on OATP1B-mediated transport of paclitaxel.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	24755470
Pubmed	Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake of Glucuronide Metabolites of Androgens.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	32587096
Pubmed	Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	26409184
Pubmed	Multiple Genetic Modifiers of Bilirubin Metabolism Involvement in Significant Neonatal Hyperbilirubinemia in Patients of Chinese Descent.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	26146841
Pubmed	Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	22695893
Pubmed	OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	29337310
Pubmed	Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	22136368
Pubmed	SLCO1B1, SLCO2B1, and SLCO1B3 polymorphisms and susceptibility to bladder cancer risk.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	24762081
Pubmed	Expression of Oatp2 in the Brain and Liver of Alzheimer Disease Mouse Model.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	31967785
Pubmed	Role of the murine organic anion-transporting polypeptide 1b2 (Oatp1b2) in drug disposition and hepatotoxicity.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	18492796
Pubmed	Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	28389619
Pubmed	Organic Anion Transporting Polypeptides Contribute to the Disposition of Perfluoroalkyl Acids in Humans and Rats.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	28013215
Pubmed	The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	19890249
Pubmed	HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	20051929
Pubmed	Impact of regulatory polymorphisms in organic anion transporter genes in the human liver.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	19620935
Pubmed	Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	26383540
Pubmed	Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	29422623
Pubmed	Identification, expression, and functional characterization of full-length and splice variants of murine organic anion transporting polypeptide 1b2.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	19400585
Pubmed	Synergistic interaction between genetics and disease on pravastatin disposition.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	24613363
Pubmed	Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	23986199
Pubmed	OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	30218633
Pubmed	Association of neonatal hyperbilirubinemia in breast-fed infants with UGT1A1 or SLCOs polymorphisms.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	25391605
Pubmed	Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	18413659
Pubmed	Full-length cDNA cloning and genomic organization of the mouse liver-specific organic anion transporter-1 (lst-1).	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	10833452
Pubmed	Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	24825069
Pubmed	Alteration in placental expression of bile acids transporters OATP1A2, OATP1B1, OATP1B3 in intrahepatic cholestasis of pregnancy.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	22203093
Pubmed	Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	18296417
Pubmed	Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	10779507
Pubmed	Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: Studies in Oatp1b2-null mice.	SLCO1B1 SLCO1B3	1.25e-06	3	23	2	20949553
Pubmed	Impact of Oatp1c1 deficiency on thyroid hormone metabolism and action in the mouse brain.	SLCO1B1 SLCO1B3	2.51e-06	4	23	2	22294745
Pubmed	Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.	SLCO1B1 SLCO1B3	2.51e-06	4	23	2	17906856
Pubmed	Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.	SLCO1B1 SLCO1B3	2.51e-06	4	23	2	20644253
Pubmed	Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.	SLCO1B1 SLCO1B3	2.51e-06	4	23	2	19442037
Pubmed	Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells.	SLCO1B1 SLCO1B3	2.51e-06	4	23	2	21849517
Pubmed	Protection against phalloidin-induced liver injury by oleanolic acid involves Nrf2 activation and suppression of Oatp1b2.	SLCO1B1 SLCO1B3	2.51e-06	4	23	2	25280775
Pubmed	Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.	SLCO1B1 SLCO1B3	2.51e-06	4	23	2	27777271
Pubmed	Associations between UGT1A1, SLCO1B1, SLCO1B3, BLVRA and HMOX1 polymorphisms and susceptibility to neonatal severe hyperbilirubinemia in Chinese Han population.	SLCO1B1 SLCO1B3	4.18e-06	5	23	2	38279097
Pubmed	OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.	SLCO1B1 SLCO1B3	4.18e-06	5	23	2	24194565
Pubmed	Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk.	SLCO1B1 SLCO1B3	4.18e-06	5	23	2	20635135
Pubmed	Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.	SLCO1B1 SLCO1B3	6.26e-06	6	23	2	20212519
Pubmed	Analysis of DNA methylation and histone modification profiles of liver-specific transporters.	SLCO1B1 SLCO1B3	6.26e-06	6	23	2	19047482
Pubmed	Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.	SLCO1B1 SLCO1B3	6.26e-06	6	23	2	22232210
Pubmed	Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters.	SLCO1B1 SLCO1B3	1.17e-05	8	23	2	19129463
Pubmed	Critical role of PPAR-alpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced downregulation of Oatp uptake transporters in mouse livers.	SLCO1B1 SLCO1B3	1.88e-05	10	23	2	18703564
Pubmed	Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties.	SLCO1B1 SLCO1B3	2.29e-05	11	23	2	14579113
Pubmed	Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.	SLCO1B1 SLCO1B3	2.29e-05	11	23	2	18695635
Pubmed	Nomenclature guidelines for X-linked mental retardation.	THOC2 IL1RAPL1	3.25e-05	13	23	2	1605216
Pubmed	Localization of Xenobiotic Transporters Expressed at the Human Blood-Testis Barrier.	SLCO1B1 SLCO1B3	4.99e-05	16	23	2	35307651
Pubmed	Changes in thyroid status during perinatal development of MCT8-deficient male mice.	SLCO1B1 SLCO1B3	6.36e-05	18	23	2	23696569
Pubmed	A genome-wide association study of the metabolic syndrome in Indian Asian men.	ZNF644 FADS1	7.10e-05	19	23	2	20694148
Pubmed	A genome-wide assessment of variability in human serum metabolism.	SLCO1B1 FADS1	7.10e-05	19	23	2	23281178
Pubmed	Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects.	SLCO1B1 SLCO1B3 SULT1A2	2.75e-04	193	23	3	19343046
Pubmed	Comprehensive Interactome Mapping of the DNA Repair Scaffold SLX4 Using Proximity Labeling and Affinity Purification.	ZNF462 RBM6 ZNF644	4.13e-04	222	23	3	37071664
Pubmed	Mitochondrial phosphoproteome revealed by an improved IMAC method and MS/MS/MS.	SLCO1B1 SLCO1B3	6.53e-04	57	23	2	17208939
Pubmed	Human metabolic individuality in biomedical and pharmaceutical research.	SLCO1B1 FADS1	6.53e-04	57	23	2	21886157
Cytoband	Ensembl 112 genes in cytogenetic band chr12p12	SLCO1B1 SLCO1B3	1.47e-03	113	23	2	chr12p12
GeneFamily	X-linked mental retardation\|Angiotensin receptors	THOC2 IL1RAPL1	8.64e-04	53	15	2	103
Coexpression	GSE1740_UNSTIM_VS_IFNA_STIMULATED_MCSF_IFNG_DERIVED_MACROPHAGE_UP	TXNDC11 PDZK1 POC1B BTN2A3P	2.31e-05	194	23	4	M6159
CoexpressionAtlas	DevelopingKidney_e15.5_Medullary collecting duct_emap-28063_k-means-cluster#1_top-relative-expression-ranked_100	PKHD1 PDZK1	3.67e-05	9	22	2	gudmap_developingKidney_e15.5_Medullary collecting duct_100_k1
ToppCell	10x5'-GI_large-bowel-Lymphocytic_T_CD4-Tregs\|GI_large-bowel / Manually curated celltypes from each tissue	PKHD1 ZNF462 NFRKB	7.70e-05	162	23	3	9a5e65c45f73a6a685b8362aa2e6aea77181caa3
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	PKHD1 ZNF462 PDZK1	9.84e-05	176	23	3	327a3e81b724252e36d786de92a3ffd721ea6d7b
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	PKHD1 ZNF462 PDZK1	1.09e-04	182	23	3	5e1b316599436740f1b30875f0ebd33c3edfb2b6
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PKHD1 ZNF462 PDZK1	1.10e-04	183	23	3	738e94b50c4c08c727d4eed0708dda08aa6891b4
ToppCell	COVID-19-kidney-PCT-S1\|kidney / Disease (COVID-19 only), tissue and cell type	PKHD1 ZNF462 PDZK1	1.12e-04	184	23	3	51ed1ebfdef45149541917c66cbacad87072e51f
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	PKHD1 ZNF462 PDZK1	1.16e-04	186	23	3	f28d72b47624b69a580b4429e2be560a26898591
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	PKHD1 ZNF462 PDZK1	1.16e-04	186	23	3	5c4ffe4e4d5536ae9f8794277fe032c693e7dd56
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	PKHD1 ZNF462 PDZK1	1.16e-04	186	23	3	b87acc80b7baa41681e4ed11d5537b9fbf5832f5
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	PKHD1 ZNF462 PDZK1	1.18e-04	187	23	3	9d77ca45f7563bd6f2a0c1be5d99d93ad30983f7
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	PKHD1 ZNF462 PDZK1	1.25e-04	191	23	3	1cb02007adb344f17ef73d58890f91298c7cf5a1
ToppCell	Tracheal-10x3prime_v2-Stromal-Schwann\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	IL34 IL1RAPL1 ZNF644	1.41e-04	199	23	3	8dc65662c3ca1db2ba0091332f0658abc0afc5de
ToppCell	Tracheal-10x3prime_v2-Stromal-Schwann-Schwann_nonmyelinating\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	IL34 IL1RAPL1 ZNF644	1.41e-04	199	23	3	a92718a3f1153b8d2196fd343ed5bc0ebc98cad7
Drug	(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid	SLCO1B1 SLCO1B3	9.76e-07	2	23	2	ctd:C561635
Drug	rifamycin SV	SLCO1B1 SLCO1B3	5.85e-06	4	23	2	ctd:C023808
Drug	microcystin-LF	SLCO1B1 SLCO1B3	5.85e-06	4	23	2	ctd:C524165
Drug	Dihydromicrocystin Lr	SLCO1B1 SLCO1B3	5.85e-06	4	23	2	CID006441227
Drug	3,5-diiodo-L-thyronine	SLCO1B1 SLCO1B3 SULT1A2	7.42e-06	38	23	3	CID000092859
Drug	2,2',4,4',5,6'-hexabromodiphenyl ether	SLCO1B1 SLCO1B3	9.74e-06	5	23	2	ctd:C555859
Drug	trospium chloride	SLCO1B1 SLCO1B3	1.46e-05	6	23	2	ctd:C003330
Drug	prednisolone phosphate	SLCO1B1 SLCO1B3	1.46e-05	6	23	2	CID000004896
Drug	estrone sulfate	SLCO1B1 SLCO1B3 SULT1A2 PDZK1	2.02e-05	163	23	4	CID000000699
Drug	nateglinide	SLCO1B1 SLCO1B3	2.04e-05	7	23	2	ctd:C060142
Drug	demethylphalloin	SLCO1B1 SLCO1B3	2.04e-05	7	23	2	CID000114793
Drug	TAK-875	SLCO1B1 SLCO1B3	2.72e-05	8	23	2	ctd:C557331
Drug	Fusidic Acid	SLCO1B1 SLCO1B3	2.72e-05	8	23	2	ctd:D005672
Drug	NSC263652	SLCO1B1 SLCO1B3	2.72e-05	8	23	2	CID000429721
Drug	5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methylbenzoic acid	SLCO1B1 SLCO1B3	3.50e-05	9	23	2	ctd:C000588958
Drug	Y-S-H	SLCO1B1 SLCO1B3	4.37e-05	10	23	2	CID000449035
Drug	repaglinide	SLCO1B1 SLCO1B3	5.34e-05	11	23	2	ctd:C072379
Drug	microcystin	SLCO1B1 SLCO1B3	5.34e-05	11	23	2	ctd:C078588
Drug	glimepiride	SLCO1B1 SLCO1B3	6.40e-05	12	23	2	ctd:C057619
Drug	Phalloidine	SLCO1B1 SLCO1B3	7.56e-05	13	23	2	ctd:D010590
Drug	AC1Q7BBT	SLCO1B1 SLCO1B3	8.82e-05	14	23	2	CID000086545
Drug	estradiol-17 beta-glucuronide	SLCO1B1 SLCO1B3	2.23e-04	22	23	2	ctd:C025483
Drug	CI-1034	SLCO1B1 SLCO1B3	2.23e-04	22	23	2	CID000157574
Drug	Clarithromycin	SLCO1B1 SLCO1B3	2.23e-04	22	23	2	ctd:D017291
Drug	perfluorobutanesulfonic acid	SLCO1B1 SLCO1B3	2.44e-04	23	23	2	ctd:C539348
Drug	estrone sulfate	SLCO1B1 SLCO1B3	2.44e-04	23	23	2	ctd:C017296
Drug	bisphenol F	SLCO1B1 SLCO1B3	2.66e-04	24	23	2	ctd:C000611646
Drug	cyanoginosin LR	SLCO1B1 SLCO1B3 PDZK1 FADS1	3.02e-04	328	23	4	ctd:C057862
Drug	Sulfobromophthalein	SLCO1B1 SLCO1B3	3.37e-04	27	23	2	ctd:D013448
Drug	Caspofungin [inn]	SLCO1B1 SLCO1B3	3.37e-04	27	23	2	CID000151068
Drug	Mesalamine	SLCO1B1 SLCO1B3	3.37e-04	27	23	2	ctd:D019804
Drug	tariquidar	SLCO1B1 SLCO1B3	3.37e-04	27	23	2	CID000148201
Drug	Dehydroepiandrosterone Sulfate	SLCO1B1 SLCO1B3	3.90e-04	29	23	2	ctd:D019314
Drug	davidigenin	SLCO1B1 SLCO1B3	4.17e-04	30	23	2	CID000442342
Drug	17beta-estradiol glucuronide	SLCO1B1 SLCO1B3	4.75e-04	32	23	2	CID000066424
Drug	fexofenadine	SLCO1B1 SLCO1B3	4.75e-04	32	23	2	ctd:C093230
Drug	4-(3,6-dimethylheptan-3-yl)phenol	SULT1A2 PDZK1	5.37e-04	34	23	2	CID010633340
Drug	norspermidine	SLCO1B1 SLCO1B3	5.69e-04	35	23	2	CID000005942
Drug	Hdel sequence	PKHD1 TXNDC11	6.36e-04	37	23	2	CID000131113
Drug	Rosuvastatin Calcium	SLCO1B1 SLCO1B3	7.81e-04	41	23	2	ctd:D000068718
Drug	BQ 123	SLCO1B1 SLCO1B3	9.83e-04	46	23	2	CID000123632
Drug	Thiocolchicoside [602-41-5]; Up 200; 7uM; PC3; HT_HG-U133A	IL1RAPL1 SLCO1B1 FAM120C	1.01e-03	198	23	3	5095_UP
Disease	Rotor syndrome	SLCO1B1 SLCO1B3	5.81e-07	2	23	2	cv:C0220991
Disease	HYPERBILIRUBINEMIA, ROTOR TYPE, DIGENIC	SLCO1B1 SLCO1B3	5.81e-07	2	23	2	C4016905
Disease	HYPERBILIRUBINEMIA, ROTOR TYPE	SLCO1B1 SLCO1B3	5.81e-07	2	23	2	237450
Disease	Rotor Syndrome	SLCO1B1 SLCO1B3	5.81e-07	2	23	2	C0220991
Disease	bilirubin metabolic disorder (implicated_via_orthology)	SLCO1B1 SLCO1B3	5.80e-06	5	23	2	DOID:2741 (implicated_via_orthology)
Disease	1-linolenoyl-GPE (18:3) measurement	SLCO1B1 FADS1	5.80e-06	5	23	2	EFO_0800365
Disease	bilirubin metabolic disorder (is_implicated_in)	SLCO1B1 SLCO1B3	8.70e-06	6	23	2	DOID:2741 (is_implicated_in)
Disease	ecosanoids measurement	SLCO1B1 SLCO1B3 FADS1	1.06e-05	55	23	3	EFO_0020044
Disease	1-eicosatrienoylglycerophosphocholine measurement	SLCO1B1 FADS1	1.22e-05	7	23	2	EFO_0021081
Disease	1-arachidonoyl-GPI (20:4) measurement	SLCO1B1 FADS1	1.22e-05	7	23	2	EFO_0800256
Disease	1-linoleoyl-GPI (18:2) measurement	SLCO1B1 FADS1	1.22e-05	7	23	2	EFO_0800266
Disease	1-eicosapentaenoyl-GPE (20:5) measurement	SLCO1B1 FADS1	1.22e-05	7	23	2	EFO_0800353
Disease	2-arachidonoyl-GPE (20:4) measurement	SLCO1B1 FADS1	1.62e-05	8	23	2	EFO_0800260
Disease	1-linoleoyl-GPE (18:2) measurement	SLCO1B1 FADS1	1.62e-05	8	23	2	EFO_0800247
Disease	deoxycholic acid glucuronide measurement	SLCO1B1 SLCO1B3	1.62e-05	8	23	2	EFO_0800575
Disease	1-arachidonoyl-GPE (20:4n6) measurement	SLCO1B1 FADS1	2.09e-05	9	23	2	EFO_0800248
Disease	hexadecenedioate (C16:1-DC) measurement	SLCO1B1 SLCO1B3	2.09e-05	9	23	2	EFO_0800562
Disease	X-21467 measurement	SLCO1B1 SLCO1B3	2.09e-05	9	23	2	EFO_0020007
Disease	citrate measurement	IL1RAPL1 SLCO1B1 FADS1	3.15e-05	79	23	3	EFO_0010114
Disease	arachidonoylcarnitine (C20:4) measurement	SLCO1B1 FADS1	3.82e-05	12	23	2	EFO_0800544
Disease	glycochenodeoxycholate glucuronide (1) measurement	SLCO1B1 SLCO1B3	4.51e-05	13	23	2	EFO_0800474
Disease	phosphatidylinositol measurement	SLCO1B1 SLCO1B3 FADS1	5.46e-05	95	23	3	EFO_0010230
Disease	cortical thickness	AGBL2 PKHD1 IL34 ZNF462 FADS1 MALRD1	1.65e-04	1113	23	6	EFO_0004840
Disease	monocyte percentage of leukocytes	SLCO1B1 USP8 CECR2 FADS1 POC1B	2.14e-04	731	23	5	EFO_0007989
Disease	lysophosphatidylethanolamine 20:4 measurement	SLCO1B1 FADS1	2.33e-04	29	23	2	EFO_0010370
Disease	MHC class I polypeptide-related sequence B measurement	SLCO1B1 USP8	2.49e-04	30	23	2	EFO_0008234
Disease	comparative body size at age 10, self-reported	PKHD1 IL34 ZNF462 SLCO1B1	2.89e-04	420	23	4	EFO_0009819
Disease	lysophosphatidylethanolamine measurement	SLCO1B1 FADS1	4.68e-04	41	23	2	EFO_0010225
Disease	urate measurement	PKHD1 RBM6 SLCO1B1 PDZK1 MALRD1	5.42e-04	895	23	5	EFO_0004531
Disease	cholestasis (biomarker_via_orthology)	SLCO1B1 SLCO1B3	6.68e-04	49	23	2	DOID:13580 (biomarker_via_orthology)
Disease	eosinophil count	THOC2 SLCO1B1 TXNDC11 FADS1 POC1B BTN2A3P	7.83e-04	1488	23	6	EFO_0004842
Disease	ceramide measurement	SLCO1B1 SLCO1B3 FADS1	7.85e-04	235	23	3	EFO_0010222
Disease	brain volume measurement	AGBL2 PKHD1 IL34 POC1B	1.07e-03	595	23	4	EFO_0006930
Disease	granulocyte percentage of myeloid white cells	USP8 FADS1 POC1B	1.15e-03	268	23	3	EFO_0007997
Disease	phospholipids in large HDL measurement	AGBL2 FADS1	1.48e-03	73	23	2	EFO_0022190

Protein segments in the cluster

Peptide	Gene	Start	Entry
FYNMRDRSHIYTFPH	BTN2A3P	431	Q96KV6
PSHMYRSYKYLNRVH	CECR2	776	Q9BXF3
NMYRLAHFSPFLYYQ	PDZK1	326	Q5T2W1
RYRYSQPHKAFTFRM	NFRKB	526	Q6P4R8
FHPSFQHNRRLYVYY	HHIPL1	256	Q96JK4
HSQMRQKHYYRSYEY	IL1RAPL1	616	Q9NZN1
MYRQRFLYSLYRHTH	POC1B	131	Q8TC44
CTFRFYYHMFGKRIY	MALRD1	941	Q5VYJ5
QYRSRLQYMKHYFPI	IL34	46	Q6ZMJ4
AEHRHRRGLMYPYIY	FAM120C	611	Q9NX05
MYRHLQYYGYFKAQR	AGBL2	21	Q5U5Z8
YMPYNHQHKYFFLIG	FADS1	256	O60427
QPTFRTTYMAYHYFR	TSEN2	336	Q8NCE0
DHMHYYQGKKYFRDR	RBM6	751	P78332
SRHFYIMPQVFHYFP	PKHD1	1566	P08F94
TALPHFFMGYYRYSK	SLCO1B1	111	Q9Y6L6
MFKTFPYQHRYRLYG	THOC2	511	Q8NI27
HMVDYQPYRKHKYSR	TEX37	21	Q96LM6
AVSYYHFYHMAKVYP	SULT1A2	136	P50226
TSLPHFFMGYYRYSK	SLCO1B3	111	Q9NPD5
KHFFYFPVIYLYHRS	TXNDC11	176	Q6PKC3
SHYLYRHKYENYRMI	ZNF644	736	Q9H582
HYQRMHPYIKFSFRY	ZNF462	861	Q96JM2
FRYYHSPTNTVHMYP	USP8	666	P40818